Tenacia Biopharmac & Golden Age Health partner to commercialize Ztalmy for CDKL5 deficiency disorder in Mainland China: Shanghai Tuesday, February 3, 2026, 12:00 Hrs [IST] Tenacia ...
Qelbree-led growth, Sage acquisition synergies, and <4x forward P/S support ~25% upside into 2026. Click for more on SUPN ...
First-ever approved treatment for CDD in China now set for commercial launch through dedicated rare disease platform Tenacia Biopharmaceuticals (Shanghai) Co., Ltd. ("Tenacia") and GOLDEN AGE HEALTH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results